SAGE Therapeutics (SAGE) Receives a Buy from Oppenheimer

Oppenheimer analyst Jay Olson assigned a Buy rating to SAGE Therapeutics (SAGE) yesterday and set a price target of $100.00. The company’s shares closed last Thursday at $74.14.

According to, Olson is a 3-star analyst with an average return of 4.1% and a 49.2% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on SAGE Therapeutics is a Moderate Buy with an average price target of $102.13, a 42.5% upside from current levels. In a report issued on May 11, Canaccord Genuity also maintained a Buy rating on the stock with a $119.00 price target.

See today’s analyst top recommended stocks >>

Based on SAGE Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.58 million and GAAP net loss of $95.76 million. In comparison, last year the company earned revenue of $2.29 million and had a GAAP net loss of $127 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts